eli lilly tirzepatide news today Diabetes drug tested for weight loss could be game changer

Eli Lilly announced that its tirzepatide franchise achieved another stellar quarter, generating $12.9 billion in sales every three months. This remarkable performance underscores the growing demand for GLP-1 drugs, which are increasingly

24.03

★★★★☆4.8 (126)

Eli Lilly has launched new self-pay options for tirzepatide, introducing 7.5 mg and 10 mg single-dose vials for $499 through the Zepbound Self Pay Journey Program. This initiative, available exclusively via LillyDirect

27.35

★★★★★4.9 (98)

Eli Lilly allows Cipla to sell weight loss drug under new brand in India

23.21

★★★★★5.0 (157)

Dr. Marc Siegel: These weight loss drugs are 'huge home runs'

28.43

★★★★★4.7 (84)

Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday. Following laboratory testing, the drugmaker said

29.46

★★★★★4.9 (203)

Lilly is selling $12.9 billion of GLP-1 drugs every three months — and expects to sell even more

22.09

★★★★★5.0 (176)

Miracle Obesity Treatment⁉️ 📢 Exciting News for Weight Loss! The FDA has granted approval to Eli Lilly for marketing their medication, tirzepatide, under a new brand name, Zepbound, for weight loss.

26.24

★★★★★4.8 (132)